Jin Medical International Ltd. filings document foreign private issuer reports furnished on Form 6-K, including Nasdaq minimum bid price compliance, shareholder meeting materials, press releases and manufacturing facility updates. The filings identify Jin Medical as a Cayman Islands exempted company with operations centered on rehabilitation medical equipment and wheelchair-related products in China.
Recent regulatory disclosures cover the company’s completed 1-for-20 share consolidation, the reclassification of its ordinary shares into Class A and Class B ordinary shares, and related amendments to its authorized share capital. The record also includes extraordinary general meeting notices, proxy materials, incorporation-by-reference language for an F-3 registration statement, and updates on the Chuzhou facility and Class I Medical Device production license.
JIN MEDICAL INTERNATIONAL LTD. has agreed to acquire contractual control of Beijing Tongsheng Technology via a variable interest entity (VIE) structure for US$105,329,974, to be paid in 64,186,456 new Class A Ordinary Shares at US$1.641 per share, subject to shareholder and regulatory approvals.
The company also plans to issue an additional 6,418,646 Class A shares to Goldeenridge Ventures Ltd. for advisory services, greatly expanding its equity base. An extraordinary meeting will vote on increasing authorized Class A shares to 15,000,000,000, raising Class B voting rights from 30 to 800 votes per share, and a related-party swap where 3,769,057 Class A shares held by Jolly Harmony are repurchased and replaced with the same number of super‑voting Class B shares, concentrating voting power while leaving economic rights unchanged.
Jin Medical International Ltd. changed its independent auditor, dismissing Audit Alliance LLP effective June 2, 2026, following board approval. Audit Alliance had audited the company for the years ended September 30, 2024 and 2025 and issued no adverse opinions, disclaimers, or qualifications.
The company reports there were no disagreements with Audit Alliance on accounting principles, financial disclosure, or audit scope, and no reportable events under Item 304(a)(1)(v)(A)-(D) of Regulation S‑K. On June 2, 2026, Jin Medical engaged Enrome LLP as its new independent registered public accounting firm for the fiscal year ending September 30, 2026.
The company also notes it had not consulted Enrome LLP on accounting matters or audit opinions during the past two fiscal years before this engagement. This report is incorporated by reference into Jin Medical’s existing Form F-3 registration statement.
Jin Medical International Ltd. director Franklin Oliver St Clair Jr filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing establishes his status as a director and provides a baseline ownership record, and it reports no transactions or trades in the company’s securities.
Jin Medical International Ltd. director TONG JAMES JIAYUAN has filed an initial Form 3, which identifies him as a director of the company. The filing data provided shows no reported share holdings or transactions, with all buy, sell, and exercise share counts listed as zero.
Jin Medical International Ltd. director Guo Yanru has filed an initial Form 3 as a reporting person for the company’s shares. The filing shows no reported share transactions, no derivative transactions, and no holding entries in this excerpt, effectively establishing a baseline for future insider ownership reports.
Jin Medical International Ltd. director and Chief Executive Officer Wang Erqi reported his beneficial ownership of the company’s ordinary shares. He beneficially owns 4,306,307 Class A Ordinary Shares through Jolly Harmony Enterprises Limited and Er Pu International Limited, and 1,000,000 Class B Ordinary Shares through Jolly Harmony Enterprises Limited, reflecting substantial indirect ownership and control over these holdings.
Jin Medical International Ltd. submitted an initial insider ownership report for Wang Ziqiang. The filing identifies him as both a director and the company’s Chief Financial Officer. The Form 3 does not report any insider share purchases, sales, or other transactions.
Jin Medical International Ltd. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company’s Class A ordinary shares closed at or above $1.00 for thirteen consecutive business days from March 16, 2026 to April 1, 2026, satisfying Nasdaq Listing Rule 5550(a)(2).
To help address the prior deficiency, the board approved a 1-for-20 share consolidation effective March 16, 2026. After this consolidation, authorized capital is 45,000,000 Class A and 5,000,000 Class B ordinary shares, and 6,827,355 Class A and 1,000,000 Class B shares are issued and outstanding.
Jin Medical International Ltd. is implementing a 1-for-20 share combination of all authorized and issued Class A and Class B ordinary shares, effective with Nasdaq on March 16, 2026. This consolidation reduces issued Class A shares from 136,547,100 to 6,827,355 and Class B shares from 20,000,000 to 1,000,000.
The move follows shareholder approval at a January 30, 2026 extraordinary general meeting and coincides with a reclassification into dual Class A and Class B shares. The company explains that this action is part of a strategic plan to maintain compliance with Nasdaq continued listing requirements and to strengthen its long-term capital structure. Class A shares will keep trading under the symbol ZJYL on a consolidation-adjusted basis, with a new CUSIP G5140V120.
Jin Medical International Ltd., a Cayman Islands holding company, files its annual 20-F describing a business that designs and manufactures wheelchairs and living aids mainly for Japan and China through a China-based VIE structure. Public shareholders own the Cayman entity, not the PRC operating company.
The filing highlights structural and regulatory risks around the VIE contracts, potential PRC policy changes, cybersecurity and overseas listing rules, and the U.S. Holding Foreign Companies Accountable Act, while noting its auditors are currently subject to PCAOB inspections. Customer concentration is high: sales to Nissin and its subsidiaries were approximately 57.3%, 78.2% and 80.5% of revenue for fiscal 2025, 2024 and 2023.
The company also discloses restrictions on capital flows, foreign exchange and dividend payments from mainland China, and reliance on PRC subsidiaries and the VIE for cash generation. As of September 30, 2024, it reports cash of about $8.1 million, short-term investments of $18.6 million, total current assets of roughly $42.8 million and total current liabilities of about $17.2 million.